Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 13/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373854 | 0.94 | CXCR3 (0.76) | CXCR3KMT2AATMRAB9ANPC1 | |
| SCHEMBL14373856 | 0.90 | CXCR3 (0.88) | CXCR3KMT2AMEN1 | |
| SCHEMBL14373250 | 0.89 | CXCR3 (0.86) | CXCR3KMT2AATMBRSK1AURKB | |
| SCHEMBL14373438 | 0.89 | CXCR3 (0.69) | CXCR3KMT2AATMRAB9ABRSK1 | |
| Bromide SCHEMBL5094976 | 0.88 | CXCR3 (0.85) | CXCR3RAB9ABRSK1AURKB | |
| SCHEMBL5449948 | 0.83 | CXCR3 (1.00) | CXCR3KMT2AATMRAB9ANPC1 | |
| SCHEMBL14373834 | 0.83 | CXCR3 (0.86) | CXCR3BRSK1AURKB | |
| SCHEMBL14373417 | 0.82 | CXCR3 (0.77) | CXCR3BRSK1AURKB | |
| SCHEMBL5461816 | 0.82 | CXCR3 (0.73) | CXCR3KMT2AATMRAB9ANPC1 | |
| SCHEMBL14373439 | 0.82 | CXCR3 (0.73) | CXCR3KMT2AATMRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885KMT2A 1857/4885ATM 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.